amlodipine has been researched along with Abdominal Obesity in 4 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engeli, S | 1 |
| Stinkens, R | 1 |
| Heise, T | 1 |
| May, M | 1 |
| Goossens, GH | 1 |
| Blaak, EE | 1 |
| Havekes, B | 1 |
| Jax, T | 1 |
| Albrecht, D | 1 |
| Pal, P | 1 |
| Tegtbur, U | 1 |
| Haufe, S | 1 |
| Langenickel, TH | 1 |
| Jordan, J | 1 |
| Eckert, S | 1 |
| Freytag, SB | 1 |
| Müller, A | 1 |
| Klebs, SH | 1 |
| Andreeva, AA | 1 |
| Ofili, EO | 1 |
| Zappe, DH | 1 |
| Purkayastha, D | 1 |
| Samuel, R | 1 |
| Sowers, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects[NCT01631864] | Phase 2 | 98 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738] | Phase 4 | 412 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement. (NCT01631864)
Timeframe: baseline, 8 weeks
| Intervention | ug/kg*min/(mmol/L*pmol/L) (Mean) |
|---|---|
| LCZ696 | 0.192 |
| Amlodipine | 0.065 |
Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean. (NCT01631864)
Timeframe: 57 days
| Intervention | micro mol/L (Geometric Mean) |
|---|---|
| LCZ696 | 82.46 |
| Amlodipine | 65.91 |
Oxidative metabolism was assessed by indirect calorimetry. (NCT01631864)
Timeframe: 57 days
| Intervention | carbon dioxide to oxygen ratio (Least Squares Mean) |
|---|---|
| LCZ696 | 0.787 |
| Amlodipine | 0.775 |
Adverse event monitoring was conducted throughout the study. (NCT01631864)
Timeframe: 8 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Adverse events (serious and non-serious) | Serious adverse events | Deaths | |
| Amlodipine | 37 | 1 | 0 |
| LCZ696 | 30 | 1 | 0 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 99.4 | 102.8 | 3.4 | 127.7 | 146.5 | 18.9 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 98.0 | 98.1 | -0.5 | 123.9 | 126.3 | 2.1 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minute) | |
| HCTZ +Amlodipine | 20.37 | 23.62 | 3.67 | 95.95 | 120.01 | 28.07 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 19.66 | 23.45 | 3.41 | 92.04 | 116.04 | 24.68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 0.47 | 0.47 | 0.00 | 0.10 | 0.10 | -0.01 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 0.45 | 0.46 | 0.01 | 0.11 | 0.10 | -0.01 |
(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Change from baseline to week 16 | |
| HCTZ +Amlodipine | 93.6 | 87.6 | 85.1 | 82.8 | 80.9 | -12.7 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 94.9 | 85.7 | 81.9 | 81.1 | 80.8 | -14.0 |
(NCT00439738)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline | |
| HCTZ +Amlodipine | 159.0 | 137.5 | -21.5 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 159.7 | 131.2 | -28.6 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of study | |
| HCTZ +Amlodipine | 69 | 102 | 112 | 140 | 146 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 91 | 123 | 122 | 124 | 133 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of Study | |
| HCTZ +Amlodipine | 18 | 23 | 46 | 65 | 68 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 33 | 59 | 57 | 62 | 68 |
1 review available for amlodipine and Abdominal Obesity
| Article | Year |
|---|---|
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complication | 2013 |
2 trials available for amlodipine and Abdominal Obesity
| Article | Year |
|---|---|
Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.
Topics: Adipose Tissue; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bl | 2018 |
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
1 other study available for amlodipine and Abdominal Obesity
| Article | Year |
|---|---|
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Imidazoles; Immune System Diseases; Inf | 2013 |